二甲双胍联合利格列汀治疗初发2型糖尿病合并NAFLD的疗效观察

Observation of the efficacy of metformin and linagliptin co-treatment for newly diagnosed type 2 diabetes mellitus with NAFLD

目的观察二甲双胍联合利格列汀治疗初发2型糖尿病合并非酒精性脂肪性肝病(NAFLD)的疗效。方法选择88例初发2型糖尿病合并NAFLD患者,按照治疗方式分为观察组(二甲双胍+利格列汀治疗)与对照组(二甲双胍治疗)。比较两组治疗前后血糖指标、胰岛功能指标、脂肪肝指标和不良反应发生情况。结果治疗后两组空腹血糖、餐后2 h血糖、糖化血红蛋白、胰岛素抵抗指数低于治疗前,胰岛素抵抗指数β高于对照组,且观察组较对照组更为显著(P<0.05)。观察组总有效率高于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论二甲双胍联合利格列汀治疗初发2型糖尿病合并NAFLD可显著改善患者胰岛功能,有助于缓解脂肪肝,且治疗安全性较高。

Aim To observe the efficacy of metformin and linagliptin co-treatment for type 2 diabetes with nonalcoholic fatty liver disease(NAFLD).Methods 88 patients with newly diagnosed type 2 diabetes mellitus complicated with NAFLD were selected and divided into the study group(metformin+linagliptin treatment)and the control group(metformin treatment)according to the treatment mode.The blood glucose indicators,pancreatic islet function,fatty liver indicators,and incidence of adverse reactions between the two groups before and after treatment were compared.Results After treatment,the fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin,and insulin resistance index of the two groups were decreased.The pancreatic isletsβcell function index was higher than the control group,and the study group was more significant than the control group(P<0.05).The total effective rate of the research group was higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Metformin and linagliptin co-treatment can significantly improve the islet function and alleviate fatty liver of newly diagnosed type 2 diabetes mellitus with NAFLD.And the treatment is safe.